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Introduction
A single human gene can potentially yield a diverse array of 
alternative mRNA isoforms, thereby expanding both the reper-
toire of gene products and subsequently the number of alternative 
proteins produced. mRNAs with different exon combinations 
are transcribed from most (up to 90%) human genes, and can 
generate variants that differ in regulatory untranslated regions, or 
encode proteins with different sub-cellular localisations and 
functions1–5. Altered splicing patterns have been suggested as 
a new hallmark of cancer cells6–8, and in prostate cancer there is 
emerging evidence that expression of specific mRNA isoforms 
derived from cancer-relevant genes may contribute to disease 
progression9–11.
Androgen steroid hormones and the androgen receptor (AR) 
play a key role in the development and progression of prostate 
cancer, with alternative splicing enabling cancer cells to produce 
constitutively active ARs11–13. The AR belongs to the nuclear 
receptor superfamily of transcription factors, and is essential 
for prostate cancer cell survival, proliferation and invasion14–16. 
Classically, androgen binding promotes AR dimerization and 
its translocation to the nucleus, where it acts as either a tran-
scriptional activator or a transcriptional repressor to dictate 
prostate specific gene expression patterns17–23. The major focus 
for prostate cancer therapeutics has been to reduce androgen 
levels through androgen deprivation therapy (ADT), either with 
inhibitors of androgen synthesis (for example, abiraterone) or 
with antagonists that prevent androgen binding to the AR (such 
as bicalutamide or enzalutamide)24. Although ADT is usually 
initially effective, most patients ultimately develop lethal 
castrate resistant disease for which there are limited treatment 
options11,12.
Androgens and other steroid hormones have also been associ-
ated with alternative splicing. Recent RNA-sequencing-based 
analysis of the androgen response of prostate cancer cells grown 
in vitro and within patients following ADT identified a set of 
700 genes whose transcription is regulated by the AR in prostate 
cancer cells25. However, in addition to regulating transcriptional 
levels, steroid hormone receptors can control exon content 
of mRNA10,26–29. In prostate cancer androgens can modulate 
the expression of mRNA isoforms via pre-mRNA process-
ing and promoter selection9,10,18,30. The AR can recruit the RNA 
binding proteins Sam68 and p68 as cofactors to influence alter-
native splicing of specific genes, and studies using minigenes 
driven from steroid responsive promoters indicate that the 
AR can affect both the transcriptional activity and alternative 
splicing of a subset of target genes11,31,32. Other steroid hor-
mones also coordinate both transcription and splicing decisions29. 
The thyroid hormone receptor (TR) is known to play a role in 
coordinating the regulation of transcription and alternative 
splicing27, and the oestrogen receptor (ER) can both regulate 
alternative promoter selection and induce alternative splic-
ing of specific gene sets that can influence breast cancer cell 
behaviour28,33–35.
In previous work we used exon level microarray analysis to identify 
7 androgen dependent changes in mRNA isoform expression10. 
However, to what extent androgen-regulated mRNA isoforms 
are expressed in clinical prostate cancer is unclear. To address 
this, here we have used RNA-Sequencing data to globally 
profile alternative isoform expression in prostate cancer cells 
exposed to androgens, and correlated the results with transcrip-
tomic data from clinical tissue. Our findings increase the number 
of known AR regulated mRNA isoforms by 10 fold and imply 
that pre-mRNA processing is an important mechanism through 
which androgens regulate gene expression in prostate cancer.
Methods
Cell culture
Cell culture was as described previously25,36. All cells were 
grown at 37°C in 5% CO2. LNCaP cells (CRL-1740, ATCC) 
were maintained in RPMI-1640 with L-Glutamine (PAA Labo-
ratories, R15-802) supplemented with 10% Fetal Bovine Serum 
(FBS) (PAA Laboratories, A15-101). For androgen treatment 
of cells, medium was supplemented with 10% dextran char-
coal stripped FBS (PAA Laboratories, A15-119) to produce a 
steroid-deplete medium. Following culture for 72 hours, 10 nM 
synthetic androgen analogue methyltrienolone (R1881) 
(Perkin-Elmer, NLP005005MG) was either added (Androgen +) 
or absent (Steroid deplete) for the times indicated.
RNA-Seq analysis
RNA-seq transcript expression analysis of previously generated 
data25 was performed according to the Tuxedo protocol37. All 
reads were first mapped to human transcriptome/genome (build 
hg19) with TopHat38/Bowtie39, followed by per-sample transcript 
assembly with Cufflinks40. The mapped data was processed 
with Cuffmerge, Cuffdiff and Cuffcompare, followed by extrac-
tion of significantly differentially expressed genes/isoforms; 
expression changes between cells grown with androgen and 
cells grown without androgens were assessed. Reference files 
for the human genome (UCSC build hg19) were downloaded 
from the Cufflinks pages: (UCSC-hg19 package from June 2012 
was used.). The software versions used for the analysis were: 
TopHat v1.4.1, SAM tools Version: 0.1.18 (r982:295), bowtie 
version 0.12.8 (64-bit) and cufflinks v1.3.0 (linked against Boost 
version 104000). The Tuxedo protocol37 was carried out as 
follows: For steps 1–5, no parameters (except for paths to input/
output files) were altered. In step 15, additional switches -s, -R, 
and -C were used when running cuffcompare. Steps 16–18 
(extraction of significant results) were performed on the command 
line.
RNA extraction, RT–PCR and real-time PCR
Cells were harvested and total RNA extracted using TRIzol 
(Invitrogen, 15596-026) according to manufacturer’s instructions. 
RNA was treated with DNase 1 (Ambion, AM2222) and cDNA 
was generated by reverse transcription of 500ng of total RNA 
using the Superscript VILO cDNA synthesis kit (Invitrogen, 
11754-050). Alternative events were analysed by either reverse 
transcriptase PCR or real-time PCR. Exon profiles were moni-
tored and quantified using the Qiaxcel capillary electrophoresis 
system (Qiagen) and percentage inclusion was calculated 
as described previously10. Real time PCR was performed in 
triplicate on cDNA using SYBR® Green PCR Master Mix 
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(Invitrogen, 4309155) and the QuantStudio 7 Flex Real-Time PCR 
System (Thermo Fisher Scientific). Samples were normalised 
using the average of three reference genes, GAPDH, β -tubulin 
and actin. Ct values for each sample were calculated using 
SDS 2.4 software (Applied Biosystems) and relative mRNA 
expression was calculated using the 2-ΔΔCt method. All primer 
sequences are listed in Supplementary Table 1. Raw Ct values 
are given in Dataset 141.
Antibodies
The following commercial antibodies were used in the study: 
anti-RLN2 rabbit monoclonal (Abcam, ab183505 1:1000 
dilution), anti-TACC2 rabbit polyclonal antibody (11407-1-AP, 
Proteintech 1:500 dilution), anti-NDUFV3 rabbit polyclonal 
antibody (13430-1-AP, Proteintech 1:500 dilution), anti-actin 
rabbit polyclonal (A2668, Sigma 1:2000 dilution), anti-α-Tubulin 
mouse monoclonal (Sigma, T5168 1:2000 dilution), normal 
rabbit IgG (711-035-152, Jackson labs 1:2000 dilution) and normal 
mouse IgG (715-036-150, Jackson labs 1:2000 dilution).
Gene ontology analysis
Gene ontology (GO) analysis of RNA-Seq data was carried out 
as described previously42. Enrichment of GO terms (with b500 
annotations) was calculated using the goseq R package (version 
1.18.0). Genes were considered significant at a p-value threshold 
of 0.05 after adjustment using the Benjamini-Hochberg false 
discovery rate.
Bioinformatic analysis of patient transcriptome data
Available clinical and processed RNA-Seq data from The Cancer 
Genome Atlas (TCGA) prostate adenocarcinoma (PRAD) cohort, 
comprising 497 tumour samples from as many patients with 
different stages / Gleason grades and 52 matched samples taken 
from normal prostate tissue (were downloaded from the Broad 
Institute TCGA Genome Analysis Center (Firehose 16/01/28 
run https://doi.org/10.7908/C11G0KM943). Transcriptome 
data from the TCGA PRAD cohort were analysed for alter-
native isoform expression, with transcript models relying on 
TCGA GAF2.1, corresponding to the University of California, 
Santa Cruz (UCSC) genome annotation from June 2011 (hg19 
assembly). This annotation encompassed 42 of the 73 androgen- 
regulated alternative mRNA isoform pairs identified. These 
were studied using two types of analysis: 1) differential tran-
script expression between tumour and normal prostate tissue and 
2) correlation between isoform expression in tumour samples and 
Gleason score or tumour stage.
Differential isoform and gene expression analysis was performed 
on estimated read counts using the limma software R package 
(version 3.7) following its RNA-Seq analysis workflow44. 
This workflow was also used for differential isoform ratio analysis, 
relying on logit-transformed ratio (see below). An FDR-adjusted 
p-value of 0.05 for the moderated t-statistics was used as thresh-
old for significance of differential expression. Individual isoform 
expression was estimated in TPM (transcripts per million 
mapped reads). The expression ratio, henceforth called PSI 
(percent spliced-in), of each annotated androgen-regulated 
isoform pair in each TCGA sample was calculated as the ratio 
between the expression of isoform 1 and the total expression 
of isoforms 1 and 2 combined, i.e. the sum of their expres-
sions. For each isoform pair, ΔPSI is the difference of median 
PSI between the tumour and the normal groups of samples.
Two-tailed Spearman’s rank correlation tests were used to study 
the association between isoform expression and both Gleason 
score and tumour stage (these were used herein as numeric 
variables). An FDR-adjusted p-value of 0.05 was used as thresh-
old for significance. Isoform expression differences between 
tumour and normal samples were considered equivalent to 
those detected in LNCaP cells under androgen stimulation 
when there was a statistically significant consistent change in 
the levels of the expected induced or repressed isoform (1 or 2), 
concomitant with no contradictory change in the PSI. Isoform 
“switches” were considered equivalent when there was a 
minimum (ΔPSI > 2.5%) and statistically significant consistent 
change in the PSI. Equivalent criteria were used to evaluate the 
equivalence between androgen-dependence and the associations 
with Gleason score and tumour stage.
Statistical analysis
Statistical analyses were conducted using the GraphPad Prism 
software (version 5.04/d). PCR quantification of mRNA isoforms 
was assessed using the unpaired student’s t-test.
Data is presented as the mean of three independent samples ± 
standard error of the mean (SEM). Statistical significance is 
denoted as * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** 
p ≤ 0.0001.
Results
Global identification of androgen-dependent mRNA isoform 
production in prostate cancer cells predicts a major role for 
alternative promoter utilisation
We analysed previously published RNAseq data from LNCaP 
cells25 to globally profile how frequently androgens drive 
production of alternative mRNA isoforms in prostate cancer 
cells. This analysis identified a group of 73 androgen regulated 
alternative mRNA isoforms, which could be validated by visu-
alisation on the UCSC Genome Browser45 (Table 1). 64 AR 
regulated mRNA isoforms were novel to this study. Experi-
mental validation in an independent RNA sample set using 
RT-PCR confirmed 17/17 of these alternative events at the mRNA 
level (Supplementary Figure 1). 73% of genes (53/73) with 
identified alternative androgen regulated mRNA isoforms also 
changed their overall expression levels in response to andro-
gens (Table 2). Some of the androgen regulated alternative 
events are in genes are already implicated in in either prostate 
cancer or other cancer types (summarised in Table 3). However, 
Gene Ontology analysis of these 73 genes did not identify any 
significantly enriched biological processes.
The 73 identified mRNA isoforms were generated via androgen- 
regulated utilisation of 56 alternative promoters, 4 alterna-
tive 3’ ends and 13 alternative splicing events (Figure 1A). 
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Table 2. Quantitative changes in gene expression in response to androgens for the 73 genes 
with AR regulated alternative mRNA isoforms.
LNCaP RNA-Seq (+/- androgens for 24 hours) Reciprocal RNA-Seq (also change in 7 patients following ADT)
No change Upregulated Downregulated No change Upregulated Downregulated
RLN2 LIG4 NUP93 LIG4 TPD52 None
DENND1A TACC2 PIK3R1 TACC2 AP2S1
RAB3IL1 RLN1 MAPRE2 NUP93 DCXR
OSBPL1A AP2S1 NDUFAF4 RLN1 PEX10
TRIM16 DCXR ACER3 RLN2 HMGCR
Sep-05 PEX10 GPRIN2 PIK3R1 ALDH1A3
RDH13 SNAPC2 TLE3 MAPRE2 FDFT1
ZFAND6 ATP6V0D1 TNRC6B NDUFAF4 GREB1
CDIP1 ARRDC1 SORBS3 SNAPC2 NCAPD3
LIMK2 KLHL36 ZNF121 ATP6V0D1 RAP1GAP
TSC22D3 VSIG10L LINC01133 ARRDC1 TMEM79
GMFB HMGCR DENND1A KRT8
MLST8 CLK3 KLHL36 ELOVL1
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LNCaP RNA-Seq (+/- androgens for 24 hours) Reciprocal RNA-Seq (also change in 7 patients following ADT)





















Of the 56 androgen regulated alternative promoters that were 
identified, 23 alternative promoters were induced by andro-
gens (including LIG4, Figure 1B), 26 promoters were repressed 
by androgens, and for 7 genes there was a switch in usage from 
one promoter to another (Table 1). The alternative splicing 
events that were under androgen control included 12 alternative 
exons and one androgen-regulated intron retention (Table 1). 
10 of these are novel to this study, including exclusion of an 
alternative exon in ZNF678 (Figure 1C). Of the alternative 
exons, six genes contained switches in previously unanno-
tated protein-coding exons in response to androgen-exposure. 
We also identified four androgen regulated alternative mRNA 3’ 
end isoform switches, including a switch in the 3’ end of the 
mRNA transcript for the MAT2A gene (Figure 1D).
Androgen regulated events control the production of 
alternative protein isoforms, non-coding RNAs and 
alternative 5’ UTRs
48/73 (66%) of the androgen regulated alternative events detected 
in response to androgen stimulation are predicted to change 
the amino acid sequence of the resulting protein (Table 1). 
Some of these are already known to have a well characterised 
role in prostate cancer progression, including an alternative 
promoter in the oncogene TPD52 that produces a protein 
isoform called PrLZ (Figure 2A)46–49. Others are not so well 
characterised. Using western blotting we could detect a 
novel shorter protein isoform corresponding to androgen-
driven selection of an alternative promoter in the TACC2 gene 
(Figure 2B); and exclusion of a cassette exon in the NDUFV3 
gene, which we show also produces a novel shorter protein iso-
form (Figure 2C). We also detected a switch in the 3’ end of the 
mRNA transcript for the MAT2A gene, which is predicted to 
produce a protein isoform with a shorter C-terminal domain 
(Figure 1D); and induction of an alternative 3’ isoform of 
CNNM2, which is predicted to be missing a conserved CBS 
domain (Table 1 and Supplementary Figure 1).
11 of the remaining identified androgen-regulated alternative 
events change the expression of mRNAs from coding to non-
coding or untranslated (not predicted to produce a protein) 
(Table 1). These included promoter switches for the RLN1 
and RLN2 genes which encode peptide hormones that may 
be important in prostate cancer5,50–55. Androgens drive a pro-
moter switch in both RLN1 and RLN2 to produce predicted 
non-coding or untranslated mRNA isoforms, reducing expres-
sion of protein-coding RLN1 and RLN2 mRNA isoforms. To 
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Table 3. Alternative events in genes previously linked to cancer.
Gene name Function Clinical importance and 
roles in other cancer 
types









Growth and prognosis of 
breast cancer56
castration-resistant growth of prostate 
cancer57
LIG4 DNA ligase with role in DNA 
repair
Prognostic marker in 
nasopharyngeal cancer58 
Upregulated in colorectal 
cancer with role in wnt 
signalling59
Predictor of poor prognosis60
RLN1 and RLN2 
 
(Relaxin1 and 2)








Well characterised role in the development 




Role in proliferation and exo- 
and endocytic pathways
Well characterised role 
in numerous cancer 
types46,66–69
Known AR target, overexpressed and 
amplified in prostate cancer70 
Oncogene in prostate cancer71 
Neuroendocrine transdifferentiation of 
prostate cancer72 
Isoform produced by alternative promoter 






squalene synthase Role in lung cancer 
metastasis75




(Transducin Like Enhancer 
Of Split 3)
Negative regulator of Wnt/β-
catenin signaling
Predictive marker for 
response to therapy 
in ovarian and breast 
cancer77,78 
Represses colon cancer 
proliferation79
Upregulated in prostate tumours80 and 




(Cyclin & CBS Domain 
Divalent Metal Cation 
Transport Mediator 2)
Magnesium transporter Proposed oncogenic role 
via increasing magnesium 
uptake82
Unknown
NUP93 Nucleoporin protein – role in 
apoptosis







Biosynthesis of  
S-adenosylmethionine, the 
principal biological methyl 
donor and precursor of 
polyamines and glutathione.
Upregulated in liver and 
colon cancer, potential 
drug target84,85 
Tumour suppressor in 
kidney carcinogenesis86 
Role in other cancer 
types87
Upregulated in prostate cancer and linked 
to cell migration via miR-34a and miR-
34b87,88
PIK3R1 PI3K regulatory subunit Underexpressed in breast 
cancer89 
High mutation frequency 
in endometrial cancer90




(Small Nuclear RNA 
Activating Complex 
Polypeptide 2)
Subunit of the snRNA-
activating protein complex. 
Necessary for RNA 









(Zinc Finger Protein 678)
Potential role in 
transcriptional regulation
Unknown Unknown
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Gene name Function Clinical importance and 
roles in other cancer 
types






Subunit of part of the 
mitochondrial respiratory 
chain
Unknown Androgen regulated alternative splice 




(Oxysterol Binding Protein 
Like 1A)






Role in retinoic acid 





(Zinc Finger Protein 121)
Potential role in 
transcriptional regulation
Interacts with MYC. 





(Solute Carrier Family 36 
Member 4)
amino acid transporter Unknown Unknown
RCAN1 
 




Inhibits NF-κB and 
suppresses lymphoma 
growth in mice94. 





(Dicarbonyl & l-xylulose 
reductase)
Role in the uronate cycle of 
glucose metabolism
Low expression 
indicates poor prognosis 
for hepatocellular 
carcinoma96. 
Role in cell adhesion97,98













Protein RP/EB Family 
Member 2)
Microtubule-associated 
protein that is necessary for 
spindle symmetry during 
mitosis












(Adaptor Related Protein 
Complex 2 Sigma 1 
Subunit)






Long non-coding RNA Poor prognosis in 
colorectal cancer101 
Upregulated and linked 





(Zinc Finger Protein 226)





(Cell death inducing p53 
target 1)




induced apoptosis in 
cancer cells103
Unknown
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Figure 1. Global identification of androgen-dependent mRNA isoform production in prostate cancer cells predicts a major role for 
alternative promoter utilisation. (A) Analysis of RNAseq data from LNCaP cells grown with (A+) or without androgens (R1881) (steroid 
deplete, SD) for 24 hours identified 73 androgen regulated alternative mRNA isoforms. The 73 alternative events were generated via 
androgen-regulated utilisation of 56 alternative promoters, 4 alternative 3' ends and 13 alternative splicing events. (B) Androgens drive a 
promoter switch in the LIG4 gene, which produces an mRNA isoform with an alternative 5’UTR. Visualisation of our LNCaP cell RNA-seq reads 
for the LIG4 gene on the UCSC genome browser identified a switch from promoter 1 to alternative promoter 2 in cells grown in the presence of 
androgens. Promoter 2 is predicted to produce a different 5’UTR without influencing the protein sequence (left panel). Quantitative PCR using 
primers specific to each promoter indicate that in response to androgens there is repression of promoter 1 and induction of promoter 2 (right 
panel). (C) Androgens drive alternative splicing of the ZNF678 gene. Visualisation of our LNCaP cell RNA-seq reads for the ZNF678 gene 
on the UCSC genome browser identified a switch to inclusion of a cassette exon in the presence of androgens. Inclusion of the alternative 
cassette exon in the ZNF678 gene is predicted to induce a switch to an alternative non-coding mRNA isoform (left panel). Quantitative PCR 
using primers in flanking exons confirmed increased inclusion of the alternative exon in LNCaP cells exposed to androgens (right panel). 
(D) Androgens promote selection of an alternative 3’ end for the MAT2A gene. Visualisation of our LNCaP cell RNA-seq reads for the MAT2A 
gene on the UCSC genome browser indicates a switch to reduced usage of an alternative 3’ end in the presence of androgens (left panel). 
Quantitative PCR using primers specific to each isoform confirmed down-regulation of an alternative 3’ end (p<0.01). Alternative 3’ ends 
for the MAT2A gene are predicted to produce proteins with different amino acid sequences and to influence a known Pfam domain (right 
panel).
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Figure 2. Androgen regulated mRNA isoform switches control alternative protein isoforms and non-coding RNAs. (A) Androgens 
induce an alternative promoter in the oncogene TPD52 that produces an isoform called PrLZ. Visualisation of our LNCaP cell RNA-seq 
reads for the TPD52 gene on the UCSC genome browser identified a switch from promoter 1 to alternative promoter 2 in cells grown in the 
presence of androgens. Promoter 2 is known to produce an alternative protein isoform of TPD52 known as PrLZ (left panel). Quantitative 
PCR using primers specific to each promoter indicate an induction of the PrLZ isoform in response to androgens (middle panel). PrLZ has an 
alternative N-terminal amino acid sequence which results in an alternative protein isoform and disrupts a known Pfam domain (right panel). 
(B) Androgens induce an alternative promoter in the TACC2 gene that produces a novel alternative protein isoform. Visualisation of our 
LNCaP cell RNA-seq reads for the TACC2 gene on the UCSC genome browser identified a switch from promoter 1 to alternative promoter 2 
in cells grown in the presence of androgens. Promoter 2 is predicted to produce an alternative shorter protein isoform of TACC2 (isoform 2) 
(left panel). Quantitative PCR using primers specific to each promoter indicate a switch from isoform 1 to isoform 2 in response to androgens 
(middle panel). Detection of TACC2 protein in LNCaP by western blotting (cells were grown with or without androgens for 24 or 48 hours). 
Tubulin was used as a loading control. Exposure to androgens for 48 hours induces expression of the alternative TACC2 protein isoform 
(right panel). (C) Androgens drive alternative splicing of the NDUFV3 gene. Visualisation of our LNCaP cell RNA-seq reads for the NDUFV3 
gene on the UCSC genome browser identified a switch to exclusion of a cassette exon in the presence of androgens (left panel). Quantitative 
PCR using primers in flanking exons confirmed less inclusion of the alternative exon in LNCaP cells exposed to androgens (middle panel). 
Exclusion of the alternative cassette exon is predicted to produce an alternative protein isoform. Detection of NDUFV3 protein in LNCaP 
cells using western blotting (right panel). (D) Androgens suppress an alternative promoter in the RLN2 gene, which produces a shorter non-
coding mRNA isoform. Visualisation of our LNCaP cell RNA-seq reads for the RLN2 gene on the UCSC genome browser identified a switch 
from promoter 1 to alternative promoter 2 in cells grown in the presence of androgens. Promoter 2 is predicted to produce an untranslated 
non-coding mRNA isoform (left panel). Quantitative PCR using primers specific to each promoter indicated a significant switch in promoter 
usage in response to androgens (middle panel). Detection of RLN2 protein in LNCaP by western blotting (cells were grown with or without 
androgens for 48 hours). Actin was used as a loading control. As seen previously55, androgens suppress RLN2 protein levels.
test whether prostate cancer cells turn off gene expression by 
switching between utilisation of promoters that generate coding 
and noncoding mRNAs, we analysed RLN2 protein levels. 
Consistent with our hypothesis and a previous study55, RLN2 
protein production was negatively regulated by androgens 
in parallel to the switch to the non-coding mRNA isoform 
(Figure 2D).
14 of the identified androgen-dependent mRNA isoforms lead 
to/result in coding mRNAs with altered 5’ untranslated regions 
(5' UTR) with no impact on the coding sequence. These include 
a promoter switch in the LIG4 gene (Figure 1B).
Differential expression of androgen-dependent mRNA 
isoforms in prostate adenocarcinoma versus normal tissue
To investigate potential links between androgen-dependent 
mRNA isoforms and tumourigenesis, we analysed the expression 
of 41 androgen-regulated mRNA isoform pairs in clinical pros-
tate adenocarcinoma and normal prostate tissues. This analysis 
utilised transcriptomic data from 497 tumour samples and 52 
normal samples in the PRAD TCGA cohort104. The remaining 
isoform pairs identified within our dataset have not been 
previously annotated by UCSC, therefore it was not possible to 
include them in our comparison. A description of the cohort used 
is summarised in Table 4.
33 of the 42 mRNA isoform pairs exhibited significant differ-
ences in the expression of at least one of the isoforms, or in the 
isoform expression ratio between tumour and normal tissues 
(Table 5). 13 of those tumour-specific alterations mimicked the 
effect of androgen stimulation in LNCaP cells: the changes were 
in form of alternative promoters for TACC2, TPD52, NUP93, 
PIK3R1, RDH13, ZFAND6, CDIP1, YIF1B, LIMK2, and FDFT1; 
an alternative 3´ end in CNNM2; and alternative exons in 




















Gleason grade (alternative gleason grade 
grouping)
1 (primary + 
secondary score ≤ 6)
50
2 (3 + 4) 171
3 (4 + 3) 123
4 (4 + 4) 93
5 (primary + 
secondary score ≥ 9)
111
All tumours were hormone naive (not subject to ADT) at 
the time of sample collection
Page 15 of 35






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 16 of 35







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 17 of 35











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 18 of 35
F1000Research 2018, 7:1189 Last updated: 17 MAY 2019
NDUFV3 and SS18 (Figure 3, Table 5 & Supplementary Figure 2). 
Two of the alternative promoters (ZFAND6 and CDIP1) are 
predicted to introduce a change in the 5'UTR, whereas all the 
others are predicted to alter the resulting protein isoform. A 
number of mRNA isoforms that were androgen responsive 
in LNCaP cells showed tumour specific alterations opposite to 
the effect of androgen stimulation. These were LIG4, MAPRE2, 
OSBPL1A, SEPT5, NR4A1, and RCAN1 (all predicted to alter 
the resulting protein isoform except LIG4). For the remaining 
14 mRNA isoform pairs, the data was inconclusive according to 
the consistency conditions listed in the methods section (Table 5).
Changes in androgen-dependent mRNA isoform 
expression during tumour progression
We next investigated whether the identified androgen-dependent 
mRNA isoforms are differentially expressed during prostate 
cancer progression by correlating the expression levels of each 
isoform with Gleason scores and prostate tumour grades within 
the PRAD TCGA cohort (Figure 4 & Figure 5, Table 6 & Table 7 
and Supplementary Figure 3 & Supplementary Figure 4). For 
6 of the alternative mRNA isoforms responsive to androgens 
(made from alternative promoters in LIG4, OSBPL1A, CLK3, 
TSC22D3 & ZNF32 and utilising an alternative exon in 
ZNF121), the expression changed significantly with Gleason 
score and showed specific alterations consistent with the effect 
of androgen stimulation. Conversely, 9 alternative isoforms 
(which were androgen responsive in LNCaP cells) showed 
tumour specific alterations opposite to the effect of androgen 
stimulation (including an alternative promoters in NUP93 and 
the alternative 3´end of MAT2A). 3 androgen regulated mRNA 
isoforms (OSBPL1A, CLK3 and TSC22D3) change significantly 
with both Gleason grade and tumour stage.
Dataset 1. Real-time PCR raw Ct values
http://dx.doi.org/10.5256/f1000research.15604.d212873
Dataset 2. Raw unedited western blot images
http://dx.doi.org/10.5256/f1000research.15604.d212874
Discussion
The main function of the androgen receptor (AR) is as a DNA 
binding transcription factor that regulates gene expression. 
Here we show the AR can couple hormone induced gene tran-
scription to alternative mRNA isoform expression in prostate 
cancer. In response to androgens, the AR can induce the use 
of alternative promoters, induce the expression of alternatively 
spliced mRNA isoforms, regulate the expression of non-coding 
mRNA transcripts, and promote the transcription of mRNA 
isoforms encoding different protein isoforms. Importantly, we 
also find that some of these alternative mRNA isoforms are 
differentially regulated in prostate cancer versus normal tissue 
and also significantly change expression during tumour progres-
sion. Our data suggest that most androgen regulated alternative 
mRNA isoforms are generated through alternative promoter 
selection rather than through internal alternative exon splicing 
mechanisms. This suggests expression of alternative isoforms 
of specific genes can be a consequence of RNA polymerase 
being recruited to different promoters in response to androgen 
stimulation. Alternative promoter usage has been observed for 
many genes and is believed to play a significant role in the 
control of gene expression4,105,106. Alternative promoter use can 
also generate mRNA isoforms with distinct functional activities 
from the same gene, sometimes having opposing functions11.
Androgen exposure further drives a smaller number of alter-
native splicing events suggesting that the AR could contribute 
to altered patterns of splicing in prostate cancer cells. Tumour 
progression is believed to be associated with a coordinated 
change in splicing patterns which is regulated by several factors 
including signalling molecules7. We also identified 4 AR 
regulated alternative mRNA 3' end isoform switches. This is 
the first time that regulation of 3' mRNA end processing has 
been shown to be controlled by androgens. The selection of 
alternative 3' ends can produce mRNA isoforms differing in 
the length of their 3' UTRs (which can lead to the inclusion 
or exclusion of regulatory elements and influence gene expres-
sion), or in their C-terminal coding region (which can contribute 
to proteome diversity)107–114. Defective 3' mRNA processing of 
numerous genes has been linked to an oncogenic phenotype115–119, 
and the 3' mRNA end profiles of samples from multiple 
cancer types significantly differ from those of healthy tissue 
samples115,119–121.
Based on the findings presented in this study, we propose that 
activated AR has the ability to coordinate both transcriptional 
activity and mRNA isoform decisions through the recruitment 
of co-regulators to specific promoters. The genomic action 
of the AR is influenced by a large number of collaborating 
transcription factors122–124. Specifically, Sam68 and p68 have been 
shown to modulate AR dependent alternative splicing of specific 
genes and are significantly overexpressed in prostate cancer31,32. 
In future work it will be important to define the role of specific 
AR co-regulators in AR mediated isoform selection.
Some of the androgen dependent mRNA isoforms identified 
here are predicted to yield protein isoforms that may be 
clinically important, or to switch off protein production via gen-
eration of noncoding mRNA isoforms. Although the functional 
significance of the alternative mRNA isoforms identified in 
this study is yet largely unexplored, as is their role in the cellu-
lar response to androgens, the presented results emphasize the 
importance of analysing gene regulation and function at the 
mRNA isoform level.
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Figure 3. Differential expression of androgen dependent mRNA isoforms in prostate cancer versus normal tissue within the PRAD 
TCGA cohort for TPD52, TACC2, NDUFV3 and CNNM2. Violin-boxplots of expression in transcripts per million mapped reads (TPM) of 
Isoforms 1 (left panel) and 2 (central panel), and of their expression ratio in PSI (right panel) in normal and tumour samples. The mean 
log2 fold-change (logFC) in expression between tumour and normal samples and the associated FDR-adjusted p-value for the moderated 
t-statistic of differential expression are shown for both isoforms (left and central panels). The mean difference in PSI (deltaPSI) between tumour 
and normal samples and the associated FDR-adjusted p-value for the Mann-Whitney U test of differential splicing are shown (right panel).
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Figure 4. Differential alternative mRNA isoform expression in the TGCA PRAD cohort across different Gleason grades for OSBPL1A, 
CLK3, TSC22D and ZNF121. Violin-boxplots of expression in transcripts per million mapped reads (TPM) of Isoforms 1 (left panel) and 2 
(central panel), and of their expression ratio (right panel) by Gleason grade. Their respective Spearman’s correlation coefficient (Rho) with 
grade and associated FDR-adjusted p-value are shown.
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Figure 5. Differential alternative mRNA isoform expression in the TGCA PRAD cohort across different tumour stages for OSBPL1A, 
CLK3 and TSC22D3. Violin-boxplots of expression in transcripts per million mapped reads (TPM) of Isoforms 1 (left panel) and 2 (central 
panel), and of their expression ratio (right panel) by tumour stage. Their respective Spearman’s correlation coefficient (Rho) with stage and 
associated FDR-adjusted p-value are shown.
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Table 6. Summarised results of the correlation analysis of androgen-regulated isoforms expression with Gleason score in the 
TCGA PRAD cohort.
Isoform 1 Isoform 2 PSI
Gene Event type Change with androgens 
(LNCap)
Rho FDR Rho FDR Rho FDR Consistency 
of change 
with Gleason
LIG4 Alternative promoter Induction of promoter 2 -0.07 1.92E-01 0.09 1.07E-01 -0.18 4.21E-04 Consistent -
TACC2 Alternative promoter Repression of promoter 1 -0.08 1.55E-01 0.01 9.26E-01 -0.08 1.88E-01 Inconclusive
TPD52 Alternative promoter Induction of promoter 2 0.00 9.51E-01 0.02 7.73E-01 0.00 9.46E-01 Inconclusive
NUP93 Alternative promoter Induction of promoter 1 -0.18 7.92E-04 -0.07 1.81E-01 0.04 4.75E-01 Opposite
RLN1 Alternative promoter Repression of promoter 2 -0.16 1.98E-03 -- -- -- -- Not assessed
AP2S1 Alternative promoter Induction of promoter 2 -0.01 8.72E-01 -- -- -- -- Not assessed
RLN2 Alternative promoter Induction of promoter 1 -0.10 6.03E-02 -- -- -- -- Not assessed
PIK3R1 Alternative promoter Repression of promoter 2 -0.07 2.51E-01 0.09 1.20E-01 -0.17 1.29E-03 Inconclusive
MAPRE2 Alternative promoter Switch to promoter 2 -0.07 1.92E-01 -0.06 2.73E-01 0.06 3.23E-01 Inconclusive
NDUFAF4 Alternative promoter Repression of promoter 2 0.00 9.79E-01 -- -- -- -- Not assessed
DCXR Alternative promoter Repression of promoter 2 -0.29 4.07E-09 -- -- -- -- Not assessed
PEX10 Alternative promoter Switch to promoter 2 0.08 1.50E-01 -- -- -- -- Not assessed
SNAPC2 Alternative promoter Switch to promoter 2 0.15 5.48E-03 -0.18 3.55E-04 0.21 5.13E-05 Opposite
ATP6V0D1 Alternative promoter Repression of promoter 2 -0.11 3.43E-02 -- -- -- -- Not assessed
ARRDC1 Alternative promoter Induction of promoter 2 0.12 2.00E-02 -- -- -- -- Not assessed
DENND1A Alternative promoter Repression of promoter 2 -0.02 8.10E-01 -- -- -- -- Not assessed
KLHL36 Alternative promoter Induction of promoter 2 -0.13 1.67E-02 -- -- -- -- Not assessed
RAB3IL1 Alternative promoter Repression of promoter 2 0.06 3.17E-01 0.32 9.13E-12 -0.02 7.15E-01 Opposite
ACER3 Alternative promoter Repression of promoter 2 0.16 3.79E-03 -- -- -- -- Not assessed
OSBPL1A Alternative promoter Induction of promoter 2 0.05 4.00E-01 0.13 1.58E-02 -0.07 2.33E-01 Consistent
TRIM16 Alternative promoter Induction of promoter 2 0.10 6.06E-02 -- -- -- -- Not assessed
VSIG10L Alternative promoter Induction of promoter 1 -0.16 1.98E-03 -- -- -- -- Not assessed
SEPT5 Alternative promoter Repression of promoter 2 0.17 1.12E-03 0.12 1.93E-02 -0.04 4.91E-01 Opposite
HMGCR Alternative promoter Repression of promoter 1 0.03 6.56E-01 -0.05 4.54E-01 0.07 2.33E-01 Inconclusive
RDH13 Alternative promoter Induction of promoter 1 0.03 7.01E-01 0.08 1.20E-01 -0.10 1.00E-01 Inconclusive
GPRIN2 Alternative promoter Repression of promoter 2 -- -- -0.01 8.93E-01 -- -- Not assessed
CLK3 Alternative promoter Repression of promoter 1 -0.13 1.58E-02 -0.05 3.98E-01 0.07 2.33E-01 Consistent
RNH1 Alternative promoter Induction of promoter 1 0.05 4.41E-01 0.07 1.83E-01 -0.01 9.23E-01 Inconclusive
ZFAND6 Alternative promoter Repression of promoter 2 0.07 1.87E-01 0.05 3.82E-01 -0.03 6.36E-01 Inconclusive
CDIP1 Alternative promoter Repression of promoter 2 0.02 8.10E-01 0.03 6.81E-01 -0.01 9.23E-01 Inconclusive
YIF1B Alternative promoter Switch to promoter 2 0.02 8.10E-01 -0.04 5.42E-01 0.05 4.39E-01 Inconclusive
LIMK2 Alternative promoter Switch to promoter 2 -0.02 8.10E-01 -0.03 6.30E-01 0.00 9.49E-01 Inconclusive
TSC22D3 Alternative promoter Repression of promoter 1 -0.15 5.15E-03 -0.01 9.26E-01 -0.09 1.14E-01 Consistent
ALDH1A3 Alternative promoter Repression of promoter 1 -0.12 2.00E-02 -- -- -- -- Not assessed
TRABD Alternative promoter Switch to promoter 2 0.14 8.04E-03 -0.04 5.43E-01 0.05 4.39E-01 Inconclusive
LIMCH1 Alternative promoter Repression of promoter 2 0.05 4.34E-01 -- -- -- -- Not assessed
GMFB Alternative promoter Induction of promoter 2 0.08 1.55E-01 -- -- -- -- Not assessed
MLST8 Alternative promoter Switch to promoter 1 0.19 5.32E-04 0.19 2.05E-04 0.07 2.14E-01 Inconclusive
TLE3 Alternative promoter Induction of promoter 2 0.05 4.28E-01 -0.10 7.19E-02 0.07 2.33E-01 Inconclusive
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Isoform 1 Isoform 2 PSI
Gene Event type Change with androgens 
(LNCap)
Rho FDR Rho FDR Rho FDR Consistency 
of change 
with Gleason
UBA1 Alternative promoter Repression of promoter 1 0.09 8.99E-02 0.03 5.95E-01 0.01 8.68E-01 Inconclusive
TNRC6B Alternative promoter Repression of promoter 2 -0.05 4.00E-01 -0.09 1.19E-01 0.09 1.11E-01 Inconclusive
FDFT1 Alternative promoter Repression of promoter 2 -0.02 7.41E-01 0.07 2.07E-01 -0.07 2.14E-01 Inconclusive
GREB1 Alternative promoter Induction of promoter 2 -0.05 4.41E-01 -0.14 5.45E-03 0.04 4.60E-01 Opposite
NCAPD3 Alternative promoter Induction of promoter 2 -0.23 3.61E-06 -- -- -- -- Not assessed
SLC36A4 Alternative promoter Induction of promoter 2 0.12 1.88E-02 -- -- -- -- Not assessed
KLC2 Alternative promoter Repression of promoter 1 -0.02 8.10E-01 0.13 1.58E-02 -0.04 4.60E-01 Inconclusive
RAP1GAP Alternative promoter Repression of promoter 1 0.01 8.79E-01 -- -- -- -- Not assessed
TMEM79 Alternative promoter Repression of promoter 1 -0.04 4.70E-01 0.15 3.46E-03 -0.09 1.11E-01 Inconclusive
NR4A1 Alternative promoter Induction of promoter 2 0.10 5.44E-02 0.00 9.79E-01 0.10 7.40E-02 Inconclusive
ZNF32 Alternative promoter Repression of promoter 2 -0.22 1.32E-05 -0.22 1.11E-05 -0.09 1.31E-01 Consistent -
C1QTNF3 Alternative promoter Induction of promoter 1 0.08 1.58E-01 -- -- -- -- Not assessed
UBE2D3 Alternative promoter Switch to promoter 2 0.18 7.24E-04 0.08 1.27E-01 -0.02 7.15E-01 Inconclusive
KRT8 Alternative promoter Repression of promoter 1 -0.05 3.81E-01 -0.16 2.07E-03 0.01 8.68E-01 Inconclusive
ELOVL1 Alternative promoter Induction of promoter 2 0.18 7.24E-04 -- -- -- -- Not assessed
RCAN1 Alternative promoter Induction of promoter 2 0.10 5.13E-02 -0.01 8.70E-01 0.12 3.69E-02 Inconclusive
SORBS3 Alternative promoter Induction of promoter 2 0.12 2.21E-02 -- -- -- -- Not assessed
MAT2A Alternative 3’ end Repression of isoform 2 0.04 5.39E-01 0.27 3.68E-08 -0.33 8.82E-13 Opposite
CNNM2 Alternative 3’ end Induction of isoform 1 -0.06 3.30E-01 0.03 5.87E-01 -0.08 2.04E-01 Inconclusive
TMEM125 Alternative 3’ end Induction of isoform 1 -- -- -0.19 2.05E-04 -- -- Not assessed
CBWD2 Alternative 3’ end Induction of isoform 2 0.13 1.37E-02 -- -- -- -- Not assessed
NDUFV3 Alternative exon Switch to isoform 2 (exon 
excluded)
0.14 8.04E-03 -0.07 2.48E-01 0.13 2.23E-02 Opposite
ZNF678 Alternative exon Switch to isoform 2 (exon 
excluded)
-0.07 1.87E-01 -- -- -- -- Not assessed
ZNF121 Alternative exon Switch to isoform 2 (exon 
excluded)
-0.13 1.63E-02 0.08 1.20E-01 -0.14 1.27E-02 Consistent
SPATC1L Alternative exon Induction of isoform 2 
(exon included)
-0.13 1.58E-02 -- -- -- -- Not assessed
MOCOS Alternative exon Switch to isoform 2 (exon 
excluded)
-0.01 8.72E-01 -- -- -- -- Not assessed
RBM45 Alternative exon Switch to isoform 2 (exon 
included)
0.12 2.45E-02 -- -- -- -- Not assessed
MIPEP Alternative exon Repression of isoform 2 
(exon excluded)
-0.14 9.92E-03 -- -- -- -- Not assessed
BBS4 Alternative exon Induction of isoform 2 
(exon included)
-0.08 1.87E-01 -- -- -- -- Not assessed
FAM195A Alternative exon Switch to isoform 1 (exon 
exluded)
0.04 5.43E-01 0.14 5.35E-03 -0.18 4.65E-04 Opposite
LINC01133 Alternative exon Induction of isoform 1 
(exon excluded)
-- -- -0.02 7.51E-01 -- -- Not assessed
SS18 Alternative exon Switch to isoform 2 (exon 
excluded)
0.04 4.86E-01 -0.06 2.51E-01 0.07 2.33E-01 Inconclusive
RHOC Alternative exon Switch to isoform 2 (exon 
excluded)
0.29 4.07E-09 0.15 4.24E-03 0.21 3.63E-05 Opposite
ZNF226 Retained intron Switch to isoform 1 (intron 
included)
0.01 8.67E-01 -0.10 7.49E-02 0.11 6.74E-02 Inconclusive
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Table 7. Summarised results of the correlation analysis of androgen-regulated isoforms expression with tumour stage in the 
TCGA PRAD cohort (related to Figure 4 and Supplementary Figure 5).
Isoform 1 Isoform 2 PSI
Gene Event type Change with androgens 
(LNCap)
Rho FDR Rho FDR Rho FDR Consistency 
of change 
with stage
LIG4 Alternative promoter Induction of promoter 2 -0.04 6.05E-01 0.02 6.82E-01 -0.09 1.82E-01 Inconclusive
TACC2 Alternative promoter Repression of promoter 1 -0.08 1.74E-01 -0.05 4.47E-01 -0.04 5.65E-01 Inconclusive
TPD52 Alternative promoter Induction of promoter 2 -0.02 7.85E-01 -0.02 6.82E-01 -0.02 7.95E-01 Inconclusive
NUP93 Alternative promoter Induction of promoter 1 -0.12 3.95E-02 0.03 6.65E-01 -0.05 4.43E-01 Opposite
RLN1 Alternative promoter Repression of promoter 2 -0.22 1.82E-05 -- -- -- -- Not assessed
AP2S1 Alternative promoter Induction of promoter 2 -0.04 5.51E-01 -- -- -- -- Not assessed
RLN2 Alternative promoter Induction of promoter 1 -0.16 5.68E-03 -- -- -- -- Not assessed
PIK3R1 Alternative promoter Repression of promoter 2 -0.02 7.92E-01 0.11 5.92E-02 -0.14 3.27E-02 Opposite -
MAPRE2 Alternative promoter Switch to promoter 2 -0.02 7.56E-01 -0.02 6.82E-01 0.03 1.00E+00 Inconclusive
NDUFAF4 Alternative promoter Repression of promoter 2 0.08 1.89E-01 -- -- -- -- Not assessed
DCXR Alternative promoter Repression of promoter 2 -0.30 6.32E-10 -- -- -- -- Not assessed
PEX10 Alternative promoter Switch to promoter 2 0.10 9.95E-02 -- -- -- -- Not assessed
SNAPC2 Alternative promoter Switch to promoter 2 0.13 2.87E-02 -0.23 5.57E-06 0.20 2.40E-04 Opposite
ATP6V0D1 Alternative promoter Repression of promoter 2 -0.11 5.43E-02 -- -- -- -- Not assessed
ARRDC1 Alternative promoter Induction of promoter 2 0.08 2.06E-01 -- -- -- -- Not assessed
DENND1A Alternative promoter Repression of promoter 2 -0.01 8.49E-01 -- -- -- -- Not assessed
KLHL36 Alternative promoter Induction of promoter 2 -0.10 1.04E-01 -- -- -- -- Not assessed
RAB3IL1 Alternative promoter Repression of promoter 2 0.08 1.71E-01 0.33 4.58E-12 0.00 9.75E-01 Opposite
ACER3 Alternative promoter Repression of promoter 2 0.16 4.77E-03 -- -- -- -- Not assessed
OSBPL1A Alternative promoter Induction of promoter 2 0.04 5.38E-01 0.13 1.59E-02 -0.07 2.88E-01 Consistent
TRIM16 Alternative promoter Induction of promoter 2 0.06 3.95E-01 -- -- -- -- Not assessed
VSIG10L Alternative promoter Induction of promoter 1 -0.12 5.43E-02 -- -- -- -- Not assessed
SEPT5 Alternative promoter Repression of promoter 2 0.11 7.96E-02 0.07 2.54E-01 -0.01 8.89E-01 Inconclusive
HMGCR Alternative promoter Repression of promoter 1 0.00 9.91E-01 -0.04 5.77E-01 0.04 6.25E-01 Inconclusive
RDH13 Alternative promoter Induction of promoter 1 -0.03 7.33E-01 0.10 7.19E-02 -0.12 9.32E-02 Inconclusive
GPRIN2 Alternative promoter Repression of promoter 2 -- -- 0.03 6.48E-01 -- -- Not assessed
CLK3 Alternative promoter Repression of promoter 1 -0.15 6.05E-03 0.02 7.76E-01 0.02 8.63E-01 Consistent
RNH1 Alternative promoter Induction of promoter 1 -0.02 7.92E-01 0.10 6.12E-02 -0.08 2.28E-01 Inconclusive
ZFAND6 Alternative promoter Repression of promoter 2 0.03 6.50E-01 0.04 5.78E-01 -0.04 6.05E-01 Inconclusive
CDIP1 Alternative promoter Repression of promoter 2 0.10 1.04E-01 0.02 7.82E-01 0.06 3.78E-01 Inconclusive
YIF1B Alternative promoter Switch to promoter 2 -0.01 8.87E-01 -0.10 6.71E-02 0.06 3.97E-01 Inconclusive
LIMK2 Alternative promoter Switch to promoter 2 0.00 9.67E-01 -0.05 4.72E-01 0.00 9.75E-01 Inconclusive
TSC22D3 Alternative promoter Repression of promoter 1 -0.13 3.44E-02 -0.07 2.54E-01 -0.03 6.59E-01 Consistent
ALDH1A3 Alternative promoter Repression of promoter 1 -0.18 7.69E-04 -- -- -- -- Not assessed
TRABD Alternative promoter Switch to promoter 2 0.06 3.95E-01 -0.03 6.48E-01 0.03 7.83E-01 Inconclusive
LIMCH1 Alternative promoter Repression of promoter 2 0.02 7.85E-01 -- -- -- -- Not assessed
GMFB Alternative promoter Induction of promoter 2 0.07 2.57E-01 -- -- -- -- Not assessed
MLST8 Alternative promoter Switch to promoter 1 0.10 8.19E-02 0.15 6.14E-03 0.02 7.83E-01 Inconclusive
TLE3 Alternative promoter Induction of promoter 2 0.03 6.38E-01 -0.11 3.84E-02 0.04 5.65E-01 Opposite
UBA1 Alternative promoter Repression of promoter 1 0.12 5.43E-02 0.00 9.72E-01 0.06 3.99E-01 Inconclusive
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Isoform 1 Isoform 2 PSI
Gene Event type Change with androgens 
(LNCap)
Rho FDR Rho FDR Rho FDR Consistency 
of change 
with stage
TNRC6B Alternative promoter Repression of promoter 2 -0.04 6.31E-01 -0.03 6.48E-01 0.02 7.83E-01 Inconclusive
FDFT1 Alternative promoter Repression of promoter 2 -0.05 4.82E-01 0.04 5.46E-01 -0.08 2.28E-01 Inconclusive
GREB1 Alternative promoter Induction of promoter 2 -0.11 7.48E-02 -0.18 7.01E-04 0.01 8.96E-01 Opposite
NCAPD3 Alternative promoter Induction of promoter 2 -0.23 1.82E-05 -- -- -- -- Not assessed
SLC36A4 Alternative promoter Induction of promoter 2 0.07 2.59E-01 -- -- -- -- Not assessed
KLC2 Alternative promoter Repression of promoter 1 -0.03 6.33E-01 0.13 1.81E-02 -0.08 2.78E-01 Inconclusive
RAP1GAP Alternative promoter Repression of promoter 1 0.02 7.85E-01 -- -- -- -- Not assessed
TMEM79 Alternative promoter Repression of promoter 1 -0.08 1.71E-01 0.16 1.97E-03 -0.10 1.20E-01 Inconclusive
NR4A1 Alternative promoter Induction of promoter 2 0.01 8.49E-01 -0.06 3.69E-01 0.08 2.62E-01 Inconclusive
ZNF32 Alternative promoter Repression of promoter 2 -0.15 6.70E-03 0.02 7.34E-01 -0.08 2.33E-01 Inconclusive
C1QTNF3 Alternative promoter Induction of promoter 1 0.03 6.74E-01 -- -- -- -- Not assessed
UBE2D3 Alternative promoter Switch to promoter 2 0.20 2.96E-04 0.07 2.17E-01 -0.02 7.83E-01 Inconclusive
KRT8 Alternative promoter Repression of promoter 1 -0.04 6.05E-01 -0.24 2.72E-06 0.04 6.05E-01 Inconclusive
ELOVL1 Alternative promoter Induction of promoter 2 0.13 2.87E-02 -- -- -- -- Not assessed
RCAN1 Alternative promoter Induction of promoter 2 0.09 1.26E-01 -0.01 8.69E-01 0.10 1.20E-01 Inconclusive
SORBS3 Alternative promoter Induction of promoter 2 0.11 7.96E-02 -- -- -- -- Not assessed
MAT2A Alternative 3’ end Repression of isoform 2 0.01 9.35E-01 0.18 7.83E-04 -0.21 8.42E-05 Opposite
CNNM2 Alternative 3’ end Induction of isoform 1 0.05 3.95E-01 0.05 4.47E-01 -0.04 6.05E-01 Inconclusive
TMEM125 Alternative 3’ end Induction of isoform 1 -- -- -0.16 2.80E-03 -- -- Not assessed
CBWD2 Alternative 3’ end Induction of isoform 2 0.08 1.74E-01 -- -- -- -- Not assessed
NDUFV3 Alternative exon Switch to isoform 2 (exon 
excluded)
0.11 7.48E-02 -0.05 4.72E-01 0.11 1.00E-01 Inconclusive
ZNF678 Alternative exon Switch to isoform 2 (exon 
excluded)
-0.02 7.43E-01 -- -- -- -- Not assessed
ZNF121 Alternative exon Switch to isoform 2 (exon 
excluded)
-0.08 1.80E-01 0.03 6.48E-01 -0.09 1.82E-01 Inconclusive
SPATC1L Alternative exon Induction of isoform 2 
(exon included)
-0.10 9.95E-02 -- -- -- -- Not assessed
MOCOS Alternative exon Switch to isoform 2 (exon 
excluded)
0.03 6.33E-01 -- -- -- -- Not assessed
RBM45 Alternative exon Switch to isoform 2 (exon 
included)
0.08 1.71E-01 -- -- -- -- Not assessed
MIPEP Alternative exon Repression of isoform 2 
(exon excluded)
-0.16 4.48E-03 -- -- -- -- Not assessed
BBS4 Alternative exon Induction of isoform 2 
(exon included)
-0.06 3.85E-01 -- -- -- -- Not assessed
FAM195A Alternative exon Switch to isoform 1 (exon 
exluded)
0.06 3.37E-01 0.10 6.85E-02 -0.10 1.20E-01 Inconclusive
LINC01133 Alternative exon Induction of isoform 1 
(exon excluded)
-- -- 0.00 9.72E-01 -- -- Not assessed
SS18 Alternative exon Switch to isoform 2 (exon 
excluded)
0.04 5.68E-01 -0.04 5.46E-01 0.06 3.97E-01 Inconclusive
RHOC Alternative exon Switch to isoform 2 (exon 
excluded)
0.15 6.05E-03 0.11 3.84E-02 0.11 1.00E-01 Inconclusive
ZNF226 Retained intron Switch to isoform 1 (intron 
included)
-0.03 6.64E-01 -0.09 1.23E-01 0.07 3.35E-01 Inconclusive
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